Cornerstone Pharmaceuticals, Inc. Receives FDA Orphan Drug Designation of CPI-613 for Treatment of Myelodysplastic Syndrome

CRANBURY, N.J., Oct. 3, 2013 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CPI-613, the Company's lead Altered Energy Metabolism Directed (AEMD) drug candidate, for the treatment of myelodysplastic syndrome (MDS).

Help employers find you! Check out all the jobs and post your resume.